{"id":1020506,"date":"2026-11-12T11:01:57","date_gmt":"2026-11-12T16:01:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-ceo-buys-more-shares-below-5-as-nthi-secures-fda-meeting-to-discuss-phase-3-trial\/"},"modified":"2026-11-12T11:01:57","modified_gmt":"2026-11-12T16:01:57","slug":"neonc-ceo-buys-more-shares-below-5-as-nthi-secures-fda-meeting-to-discuss-phase-3-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-ceo-buys-more-shares-below-5-as-nthi-secures-fda-meeting-to-discuss-phase-3-trial\/","title":{"rendered":"NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial"},"content":{"rendered":"

\nRecent purchases total 150,000 shares as NeOnc prepares to discuss potential accelerated approval and a Phase 3 confirmatory trial for NEO100
\n<\/h2>\n
\n

DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) — (www.InvestorsTape.com<\/a>)\u2014 NeOnc Technologies Holdings (NASDAQ: NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares in the open market<\/strong>, bringing his recent purchases to 150,000 shares<\/strong> as the company approaches important clinical and regulatory milestones.<\/p>\n

The latest transactions represent approximately $294,500<\/strong>, with purchases reaching $4.49 per share<\/strong>. Combined with the preceding 80,000-share purchases announced by NeOnc, Heshmatpour committed approximately $563,582 across November 5\u201311<\/strong>.<\/p>\n

\n Our bullish interpretation: the CEO continues putting personal capital behind his conviction as NeOnc\u2019s development story advances.<\/strong>\n <\/p>\n

\n The CEO Keeps Buying Higher<\/strong>\n <\/p>\n

The latest filing summary details three purchases:<\/p>\n\n\n\n\n\n\n
\n Transaction date<\/strong>\n <\/td>\n\n Shares purchased<\/strong>\n <\/td>\n\n Reported price<\/strong>\n <\/td>\n<\/tr>\n
November 10<\/td>\n50,000<\/td>\n$4.192 weighted average<\/td>\n<\/tr>\n
November 11<\/td>\n10,000<\/td>\n$4.49<\/td>\n<\/tr>\n
November 11<\/td>\n10,000<\/td>\n$4.00<\/td>\n<\/tr>\n
\n Total<\/strong>\n <\/td>\n\n 70,000<\/strong>\n <\/td>\n\n Approximately $4.207 average<\/strong>\n <\/td>\n<\/tr>\n<\/table>\n

The transactions increased Heshmatpour\u2019s reported direct holdings to 3,333,000 shares<\/strong>, separate from his indirectly held positions.<\/p>\n

NeOnc previously announced purchases of 80,000 shares across November 5, 6 and 9<\/strong>, totaling approximately $269,082<\/strong> using personal funds.<\/p>\n

\n The progression stands out.<\/strong> Earlier purchases came in the low-to-mid $3 range. The CEO continued adding above $4, including a transaction at $4.49.<\/p>\n

These open-market purchases increase his ownership as investors evaluate the company\u2019s next milestones. Roth MKM also recently reaffirmed its Buy rating and $20 price target<\/strong>, maintaining its bullish valuation.<\/p>\n

\n FDA Meeting Puts Phase 3 and Accelerated Approval on the Agenda<\/strong>\n <\/p>\n

On November 11, NeOnc announced that the FDA granted a Type B End-of-Phase meeting scheduled for early January 2027<\/strong> to discuss a potential accelerated approval pathway for intranasal NEO100.<\/p>\n

NeOnc intends to seek feedback on whether its clinical and nonclinical evidence could support an accelerated approval application for recurrent or progressive IDH-mutant grade 4 astrocytoma<\/strong>.<\/p>\n

The company will also seek agreement on NEO100-012, a proposed randomized Phase 3 trial<\/strong> comparing NEO100 with investigator-selected standard-of-care chemotherapy. Overall survival would be the primary endpoint<\/strong>, with the study intended to provide registrational and confirmatory evidence.<\/p>\n

\n NeOnc now has an FDA discussion scheduled around a potential approval pathway and the design of a Phase 3 trial.<\/strong> Positive Phase 2a findings provide the foundation for that discussion and give investors a defined next step to follow.<\/p>\n

\n Two Programs. Several Dates to Watch.<\/strong>\n <\/p>\n

The January meeting adds to an already active calendar:<\/p>\n